Cargando…
Challenges in assessing population reach in a pragmatic trial
Strategies and Opportunities to STOP Colon Cancer in Priority Populations (STOP CRC) was a pragmatic cluster-randomized trial conducted at federally qualified health centers and designed to “Reach” as many unscreened patients as possible by directly mailing them fecal screening tests. STOP CRC used...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6558213/ https://www.ncbi.nlm.nih.gov/pubmed/31198661 http://dx.doi.org/10.1016/j.pmedr.2019.100910 |
_version_ | 1783425583725674496 |
---|---|
author | Green, Beverly B. Vollmer, William M. Keast, Erin Petrik, Amanda F. Coronado, Gloria D. |
author_facet | Green, Beverly B. Vollmer, William M. Keast, Erin Petrik, Amanda F. Coronado, Gloria D. |
author_sort | Green, Beverly B. |
collection | PubMed |
description | Strategies and Opportunities to STOP Colon Cancer in Priority Populations (STOP CRC) was a pragmatic cluster-randomized trial conducted at federally qualified health centers and designed to “Reach” as many unscreened patients as possible by directly mailing them fecal screening tests. STOP CRC used an electronic health record registry to identify individuals' needing CRC screening and mail interventions to them. The registry was updated daily removing individuals completing CRC screening or those who no longer were clinic patients. Reach, a component RE-AIM (Reach, Effectiveness, Adoption, Implementation, and Maintenance), is defined as the absolute number, percent, and representativeness of individuals “willing to participate in” or “exposed to” an initiative. We describe the complexities of measuring Reach in a pragmatic trial. Overall 21,134 patients were on the registry list for at least one day, with 18,226 remaining after removing patients completing screening before any mailings. Observed Reached (the percent of individuals exposed to the intervention) using each denominator was 30.7% and 35.6% respectively. Reach improved only modestly after accounting for factors that made it impossible for clinics to send mailings. Few differences were observed in demographic and health care utilization factors among individuals Reached versus not Reached, suggesting that health center Implementation was more influential than patients' willingness or ability to participate. A pragmatic definition of Reach that accounted for dynamic changes the absolute number eligible and the proportion exposed was more useful than traditional definitions of Reach. Actual Reach was dependent on Implementation and not patient level characteristics. Clinical Trials Registration Number: ClincalTrials.gov (NCT01742065). |
format | Online Article Text |
id | pubmed-6558213 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-65582132019-06-13 Challenges in assessing population reach in a pragmatic trial Green, Beverly B. Vollmer, William M. Keast, Erin Petrik, Amanda F. Coronado, Gloria D. Prev Med Rep Regular Article Strategies and Opportunities to STOP Colon Cancer in Priority Populations (STOP CRC) was a pragmatic cluster-randomized trial conducted at federally qualified health centers and designed to “Reach” as many unscreened patients as possible by directly mailing them fecal screening tests. STOP CRC used an electronic health record registry to identify individuals' needing CRC screening and mail interventions to them. The registry was updated daily removing individuals completing CRC screening or those who no longer were clinic patients. Reach, a component RE-AIM (Reach, Effectiveness, Adoption, Implementation, and Maintenance), is defined as the absolute number, percent, and representativeness of individuals “willing to participate in” or “exposed to” an initiative. We describe the complexities of measuring Reach in a pragmatic trial. Overall 21,134 patients were on the registry list for at least one day, with 18,226 remaining after removing patients completing screening before any mailings. Observed Reached (the percent of individuals exposed to the intervention) using each denominator was 30.7% and 35.6% respectively. Reach improved only modestly after accounting for factors that made it impossible for clinics to send mailings. Few differences were observed in demographic and health care utilization factors among individuals Reached versus not Reached, suggesting that health center Implementation was more influential than patients' willingness or ability to participate. A pragmatic definition of Reach that accounted for dynamic changes the absolute number eligible and the proportion exposed was more useful than traditional definitions of Reach. Actual Reach was dependent on Implementation and not patient level characteristics. Clinical Trials Registration Number: ClincalTrials.gov (NCT01742065). Elsevier 2019-05-29 /pmc/articles/PMC6558213/ /pubmed/31198661 http://dx.doi.org/10.1016/j.pmedr.2019.100910 Text en © 2019 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Regular Article Green, Beverly B. Vollmer, William M. Keast, Erin Petrik, Amanda F. Coronado, Gloria D. Challenges in assessing population reach in a pragmatic trial |
title | Challenges in assessing population reach in a pragmatic trial |
title_full | Challenges in assessing population reach in a pragmatic trial |
title_fullStr | Challenges in assessing population reach in a pragmatic trial |
title_full_unstemmed | Challenges in assessing population reach in a pragmatic trial |
title_short | Challenges in assessing population reach in a pragmatic trial |
title_sort | challenges in assessing population reach in a pragmatic trial |
topic | Regular Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6558213/ https://www.ncbi.nlm.nih.gov/pubmed/31198661 http://dx.doi.org/10.1016/j.pmedr.2019.100910 |
work_keys_str_mv | AT greenbeverlyb challengesinassessingpopulationreachinapragmatictrial AT vollmerwilliamm challengesinassessingpopulationreachinapragmatictrial AT keasterin challengesinassessingpopulationreachinapragmatictrial AT petrikamandaf challengesinassessingpopulationreachinapragmatictrial AT coronadogloriad challengesinassessingpopulationreachinapragmatictrial |